A migraine attack is more than a headache. It can derail your entire day.

AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational ...

It can also be taken as needed for acute migraine treatment. However, no more than 18 doses can be taken in 30 days. Common side effects include nausea, stomach pain, and indigestion. Qulipta ...

and newer products like migraine treatment Qulipta. Clinical disappointments and patent cliffs will happen, but AbbVie looks ready to handle them all. The company's pipeline has several dozen ...

AbbVie’s oral CGRP inhibitor Qulipta (atogepant) is also under review by NICE for migraine prevention, with a decision due in mid-August. “On top of debilitating physical symptoms, migraine ...

migraine treatment Qulipta, and others. AbbVie's current crop of growth drivers will also run out of patent exclusivity eventually, but it says a lot that the company can survive one of the ...

The latter isn't going to happen of course. AbbVie recorded sales of more than $1.2 billion for Ubrelvy and partner migraine drug Qulipta for episodic and chronic migraine prevention last year.

Brukinsa may interact with certain CGRP antagonists, which are used to treat and help prevent migraine ... interact with Brukinsa include atogepant (Qulipta) and ubrogepant (Ubrelvy).